BC Extra | Jan 14, 2020
Financial News

Tyra raises $50M series A for cancer drug resistance

Tyra Biosciences emerged from stealth with a $50 million series A round to bring its first therapy to the clinic for drug-resistant cancer. Alta Partners, RA Capital Management, Boxer Capital of Tavistock Group and Canaan...
BC Extra | Jun 14, 2019
Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

Flatiron Health Inc. hired Michael Vasconcelles as CMO. Vasconcelles, who was CMO of Unum Therapeutics Inc. (NASDAQ:UMRX), succeeds Amy Abernethy, who left to join FDA as principal deputy commissioner early this year. The Roche (SIX:ROG;...
BC Extra | May 21, 2019
Company News

Merck bets on HIF2As with Peloton takeout ahead of planned listing

Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck &...
BC Extra | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) hired Frederick Hausheer as CMO. He was CEO of Alpha Omega Oncology Services (San Antonio, Texas) and an associate partner at Alacrita Consulting (Waltham, Mass.). Antibody company Kymab Group...
BC Week In Review | Dec 1, 2017
Clinical News

CHMP recommends pediatric label expansion for Merck's Cubicin

EMA's CHMP recommended approval of a label expansion for Cubicin daptomycin (MK-3009) from Merck & Co. Inc. (NYSE:MRK) to include patients ages 1-17 with Staphylococcus aureus bacteremia associated with complicated skin or soft-tissue infections (cSSTI)....
BC Extra | Oct 24, 2017
Company News

Management tracks: Five Prime, CytoSen

Cancer play Five Prime Therapeutics Inc. (NASDAQ:FPRX) promoted Aron Knickerbocker to president and CEO from COO, effective Jan. 1, 2018. He succeeds Lewis Williams, who will become executive chairman. Cell therapy company CytoSen Therapeutics Inc....
BC Week In Review | Sep 22, 2017
Financial News

Flagship Pioneering unveils microbiome-focused company Kaleido

On Sept. 18, Flagship Pioneering announced Kaleido Biosciences Inc. (Bedford, Mass.), a biopharmaceuticals company that uses its chemistry platform to discover and develop products that modulate the metabolic profile of the microbiome in order to...
BC Extra | Sep 18, 2017
Financial News

Flagship Pioneering unveils microbiome-focused company

Flagship Pioneering announced Kaleido Biosciences Inc. (Bedford, Mass.), a biopharmaceuticals company that uses its chemistry platform to discover and develop products that modulate the metabolic profile of the microbiome in order to treat and prevent...
BioCentury | Mar 10, 2017
Finance

A fever for infectious

A two-year search for an infectious disease investment led GV to Spero Therapeutics LLC , whose platform technology, management and investor syndicate proved to be the winning combination. “We had been looking in the antibiotics space...
BC Week In Review | Nov 4, 2016
Company News

Cempra, Toyama milestone payment

Cempra received a $10 million milestone payment from Toyama under a 2013 deal granting Toyama exclusive rights to develop and commercialize solithromycin in Japan. The payment was triggered by the start of a Japanese Phase...
Items per page:
1 - 10 of 907
BC Extra | Jan 14, 2020
Financial News

Tyra raises $50M series A for cancer drug resistance

Tyra Biosciences emerged from stealth with a $50 million series A round to bring its first therapy to the clinic for drug-resistant cancer. Alta Partners, RA Capital Management, Boxer Capital of Tavistock Group and Canaan...
BC Extra | Jun 14, 2019
Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

Flatiron Health Inc. hired Michael Vasconcelles as CMO. Vasconcelles, who was CMO of Unum Therapeutics Inc. (NASDAQ:UMRX), succeeds Amy Abernethy, who left to join FDA as principal deputy commissioner early this year. The Roche (SIX:ROG;...
BC Extra | May 21, 2019
Company News

Merck bets on HIF2As with Peloton takeout ahead of planned listing

Days before Peloton was to price an IPO that would fund Phase III testing of its HIF2A program to treat kidney cancer, the biotech has elected instead to take a buyout offer from Merck &...
BC Extra | Apr 8, 2019
Company News

Management tracks: WuXi AppTec, Kymab, Acceleron

WuXi AppTec Co. Ltd. (Shanghai:603259; HKSE:2359) hired Frederick Hausheer as CMO. He was CEO of Alpha Omega Oncology Services (San Antonio, Texas) and an associate partner at Alacrita Consulting (Waltham, Mass.). Antibody company Kymab Group...
BC Week In Review | Dec 1, 2017
Clinical News

CHMP recommends pediatric label expansion for Merck's Cubicin

EMA's CHMP recommended approval of a label expansion for Cubicin daptomycin (MK-3009) from Merck & Co. Inc. (NYSE:MRK) to include patients ages 1-17 with Staphylococcus aureus bacteremia associated with complicated skin or soft-tissue infections (cSSTI)....
BC Extra | Oct 24, 2017
Company News

Management tracks: Five Prime, CytoSen

Cancer play Five Prime Therapeutics Inc. (NASDAQ:FPRX) promoted Aron Knickerbocker to president and CEO from COO, effective Jan. 1, 2018. He succeeds Lewis Williams, who will become executive chairman. Cell therapy company CytoSen Therapeutics Inc....
BC Week In Review | Sep 22, 2017
Financial News

Flagship Pioneering unveils microbiome-focused company Kaleido

On Sept. 18, Flagship Pioneering announced Kaleido Biosciences Inc. (Bedford, Mass.), a biopharmaceuticals company that uses its chemistry platform to discover and develop products that modulate the metabolic profile of the microbiome in order to...
BC Extra | Sep 18, 2017
Financial News

Flagship Pioneering unveils microbiome-focused company

Flagship Pioneering announced Kaleido Biosciences Inc. (Bedford, Mass.), a biopharmaceuticals company that uses its chemistry platform to discover and develop products that modulate the metabolic profile of the microbiome in order to treat and prevent...
BioCentury | Mar 10, 2017
Finance

A fever for infectious

A two-year search for an infectious disease investment led GV to Spero Therapeutics LLC , whose platform technology, management and investor syndicate proved to be the winning combination. “We had been looking in the antibiotics space...
BC Week In Review | Nov 4, 2016
Company News

Cempra, Toyama milestone payment

Cempra received a $10 million milestone payment from Toyama under a 2013 deal granting Toyama exclusive rights to develop and commercialize solithromycin in Japan. The payment was triggered by the start of a Japanese Phase...
Items per page:
1 - 10 of 907